SALT LAKE CITY, Feb. 14, 2011 /PRNewswire/ -- Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, announced today that it has acquired the Efficacy Pharmacology operating unit of Ricerca Biosciences, LLC., located in Bothell, WA.
The acquisition brings a state-of-the-art, GLP compliant facility, with a highly talented team, and a broad range of laboratory capabilities to Numira. “The Bothell site has a long- standing, strong reputation in the CRO market and possesses deep scientific expertise in several therapeutic areas that complement Numira’s imaging technology,” said Michael Beeuwsaert, CEO of Numira. “By combining our respective strengths, we are well positioned to provide even greater value to both Numira’s and Ricerca’s clients, and pursue new opportunities for growth.” With this transaction, Numira is able to offer clients comprehensive solutions that include in-life models and studies, high-resolution quantitative imaging, histology, and immunohistochemistry services.
Numira will immediately begin integrating the two companies’ services, operations, and employees to ensure a smooth transition of clients and projects.
About Numira Biosciences
Numira Biosciences is a rapidly-growing, specialty contract research organization (CRO) that provides powerful imaging solutions for researchers attempting to answer questions related to the onset and progression of disease, drug efficacy, and drug safety in animal models. Through the combination of proprietary stains, high performance imaging software, and MicroCT scanners, we offer a dramatic change in how data is captured, visualized, and analyzed. Numira, a privately-held company, is venture- backed by vSpring Capital, Crocker Ventures, and the Tech Coast Angels. For more information on Numira, please visit www.numirabio.com
SOURCE Numira Biosciences
